Haemonetics (HAE) FY2018 results: revenue $904 million, up 2.0% on the year
Haemonetics Corp. (HAE) reported revenue of $904 million for fiscal 2018, the year ended 31 March 2018, up 2.0% on the year before. Net income was $46 million, and diluted earnings per share $0.85. The figures are the company's own, from the 10-K it filed with the SEC on 22 May 2019.
Revenue
$904 million
+2.0% on the year
FY2011FY2018
Operating margin
6.2%
-2.2% a year earlier
FY2011FY2018
Net income
$46 million
FY2011FY2018
Diluted EPS
$0.85
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
904
886
909
+2.0%
Cost of revenue
492
508
503
-3.1%
Gross profit
412
378
406
+8.8%
Gross margin
45.6%
42.7%
44.7%
Research and development
39.2
37.6
45.0
+4.5%
Selling, general and administrative
317
302
317
+4.9%
Operating income
56.2
-19.4
-43.9
Operating margin
6.2%
-2.2%
-4.8%
Interest expense
7.7
n/a
n/a
Pre-tax income
59.6
-27.5
-53.4
Income tax
14.1
-1.2
2.2
Effective tax rate
23.6%
n/a
n/a
Net income
45.6
-26.3
-55.6
Net margin
5.0%
-3.0%
-6.1%
Diluted EPS
$0.85
-$0.51
-$1.09
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
220
160
122
+37.9%
Capital expenditure
74.8
76.1
102
-1.8%
Free cash flow
146
83.6
19.5
+74.1%
Free cash flow margin
16.1%
9.4%
2.1%
Cash from investing
-63.0
-73.3
-105
Cash from financing
-121
-60.4
-62.6
Depreciation and amortisation
89.2
89.7
89.9
-0.5%
Share-based compensation
13.0
9.2
6.9
+42.3%
Buybacks
100
0.0
61.0
Diluted shares, weighted
54m
52m
51m
+3.8%
Shares outstanding at period end
52m
52m
51m
+0.2%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
752
740
722
+1.7%
Debt
254
316
408
-19.7%
Other liabilities
231
183
189
+26.2%
Total liabilities and equity
1,237
1,239
1,319
-0.1%
Fixed assets
332
324
338
+2.6%
Goodwill
211
211
268
+0.3%
Intangible assets
157
178
204
-11.8%
Cash and equivalents
180
140
115
+29.1%
Receivables
151
153
157
-1.0%
Inventory
161
177
187
-9.1%
Other assets
45.0
57.3
50.0
-21.4%
Total assets
1,237
1,239
1,319
-0.1%
10-K for the year ended 31 March 2018, filed 22 May 2019: the filing.